FDA
approval
· 2017-01-04
FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
Summary
The FDA approved a supplemental application to approve Pristiq Extended-Release (desvenlafaxine succinate) as a new extended-release formulation from Wyeth Phar…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)